Stock DADI DAR AL DAWA DEVELOPMENT AND INVESTMENT CO. LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Dar Al Dawa Development and Investment Co. Ltd.

Equities

DADI

JO4101211012

Pharmaceuticals

End-of-day quote Amman S.E.
Other stock markets
 06:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
1.31 JOD -2.24% Intraday chart for Dar Al Dawa Development and Investment Co. Ltd. -6.43% -0.76%
Mar. 31 Dar Al Dawa Development and Investment Co. Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Dar Al Dawa Development and Investment Co. Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 22.25 26.5 28.75 40.25 37.45 46.2
Enterprise Value (EV) 1 65.29 75.12 68.35 68.83 62.84 72.66
P/E ratio -5.53 x -3.61 x 3.31 x 36.9 x 16.1 x 14.6 x
Yield - - - - 4.67% -
Capitalization / Revenue 0.4 x 0.48 x 0.54 x 0.78 x 0.62 x 0.62 x
EV / Revenue 1.19 x 1.37 x 1.29 x 1.33 x 1.04 x 0.97 x
EV / EBITDA 65.2 x 989 x 9.38 x 10.1 x 7.48 x 7.02 x
EV / FCF -99.5 x -46.6 x -111 x 62.7 x 20.1 x -73 x
FCF Yield -1.01% -2.15% -0.9% 1.6% 4.98% -1.37%
Price to Book 0.63 x 1.13 x 0.92 x 0.96 x 0.86 x 1.01 x
Nbr of stocks (in thousands) 25,000 25,000 25,000 35,000 35,000 35,000
Reference price 2 0.8900 1.060 1.150 1.150 1.070 1.320
Announcement Date 3/31/19 5/18/20 5/11/21 3/31/22 3/31/23 3/31/24
1JOD in Million2JOD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 55.1 54.86 53.15 51.77 60.36 74.88
EBITDA 1 1.002 0.076 7.287 6.834 8.397 10.36
EBIT 1 -2.165 -3.208 3.684 3.375 4.878 6.96
Operating Margin -3.93% -5.85% 6.93% 6.52% 8.08% 9.3%
Earnings before Tax (EBT) 1 -5.101 -6.981 8.959 0.9058 2.57 2.583
Net income 1 -4.024 -7.344 8.678 1.052 2.323 3.161
Net margin -7.3% -13.39% 16.33% 2.03% 3.85% 4.22%
EPS 2 -0.1610 -0.2938 0.3470 0.0311 0.0664 0.0903
Free Cash Flow 1 -0.6563 -1.613 -0.6159 1.099 3.127 -0.9953
FCF margin -1.19% -2.94% -1.16% 2.12% 5.18% -1.33%
FCF Conversion (EBITDA) - - - 16.08% 37.24% -
FCF Conversion (Net income) - - - 104.46% 134.61% -
Dividend per Share - - - - 0.0500 -
Announcement Date 3/31/19 5/18/20 5/11/21 3/31/22 3/31/23 3/31/24
1JOD in Million2JOD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 43 48.6 39.6 28.6 25.4 26.5
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 42.97 x 639.9 x 5.435 x 4.183 x 3.023 x 2.555 x
Free Cash Flow 1 -0.66 -1.61 -0.62 1.1 3.13 -1
ROE (net income / shareholders' equity) -10% -26.6% 30.3% 2.46% 5.1% 6.89%
ROA (Net income/ Total Assets) -1.29% -1.93% 2.29% 2.1% 2.94% 4.02%
Assets 1 311.4 381.2 379.4 50.08 78.92 78.64
Book Value Per Share 2 1.410 0.9400 1.240 1.190 1.240 1.310
Cash Flow per Share 2 0.1200 0.0700 0.4200 0.3200 0.3900 0.3600
Capex 1 7.08 2.23 2.09 1.36 1.67 2.07
Capex / Sales 12.84% 4.06% 3.92% 2.64% 2.76% 2.76%
Announcement Date 3/31/19 5/18/20 5/11/21 3/31/22 3/31/23 3/31/24
1JOD in Million2JOD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
DAR AL DAWA DEVELOPMENT AND INVESTMENT CO. LTD. Stock Dar Al Dawa Development and Investment Co. Ltd.
-0.76% 64.68M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. DADI Stock
  4. Financials Dar Al Dawa Development and Investment Co. Ltd.